Skip to content

Acute Myeloid Leukemia T 1 11 Q21 Q23 Cn305537

Published: July 22, 2026Updated: August 20, 2026

A blood cancer involving a chromosomal translocation between chromosomes 1 and 11, affecting the KMT2A gene. This rearrangement is seen in both adults and children and is generally associated with a poorer prognosis, often requiring intensive treatment.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 20, 2026Editorial policy

Key facts at a glance

ICD-10
C96.9
ICD-11
2A00.0
Body system
hematologic
Severity
severe
Chronic
false

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Warning signs - seek immediate care

!

Neurological symptoms

Fever

(hematologic)

Generalized symptoms

(hematologic)

Significant symptoms that substantially affect daily functioning.

Frequency: Varies

Fatigue

(hematologic)

Bone pain

(musculoskeletal)

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

AML-Directed Induction Chemotherapy

Combination chemotherapy with cytarabine and anthracycline to achieve morphological remission. Standard of care for medically fit patients with this translocation.

medication
2

Combination drug regimen with regular assessment

Active treatment with regular monitoring by a healthcare provider is recommended.

medication
3

Consolidation Chemotherapy

Additional cycles of high-dose cytarabine following induction to eliminate residual disease and prevent relapse. Typically 2-4 cycles depending on risk stratification.

procedure

Additional treatment options

Allogeneic Stem Cell Transplantation

Considered for high-risk patients with this translocation. Provides graft-versus-leukemia effect which may overcome adverse cytogenetic features.

procedure

Maintenance Therapy

Lower intensity ongoing treatment after consolidation to maintain remission. May include hypomethylating agents or targeted therapies based on molecular findings.

medication

Serial Bone Marrow Assessment

Regular monitoring of treatment response through bone marrow biopsies and molecular testing. Essential for detecting relapse early and guiding further therapy decisions.

monitoring

When to seek medical help

Recognize when you need immediate medical attention.

See a doctor within 24 hours

Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.

Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.

Frequently asked questions

Common questions about this topic.

Q

What is Acute Myeloid Leukemia T 1 11 Q21 Q23 Cn305537?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Sources and references

Authoritative medical sources used to create this content.

1

Dohner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115(3):453-474.

guideline2010
2

Meyer C, Burmeister T, Groger D, et al. The MLL recombinome of acute leukemias in 2017. Leukemia. 2018;32(2):273-284.

review2018
3

Krivtsov AV, Figueroa ME, Sinha AU, et al. Cell of origin determines clinically relevant subtypes of MLL-rearranged AML. J Clin Invest. 2013;123(2):725-733.

clinical_trial2013
4

Schoch C, Schnittger S, Klaus M, Kern W, Hiddemann W, Haferlach T.AML with 11q23/MLL abnormalities as defined by the WHO classification: incidence, partner chromosomes, FAB subtype, age distribution, and prognostic impact in an unselected series of 1897 cytogenetically analyzed AML cases. Blood. 2003;102(7):2395-2402.

meta_analysis2003

Medication Comparisons

Compare medications used to treat Acute Myeloid Leukemia T 1 11 Q21 Q23 Cn305537. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy